Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study

Patients with multiple basal cell carcinoma (BCC), including those with Gorlin syndrome, require long-term vismodegib treatment, but this may be limited by low-grade toxicity. Multiple lesions can impact a patientu0027s emotional, physical, and social functioning.(1-3) However, data are limited concerning health-related quality of life (HRQoL) in patients with BCC.(1) The MIKIE study (ClinicalTrials.gov, NCT01815840) assessed two intermittent vismodegib schedules in adult patients with multiple BCCs. In the primary analysis, both schedules showed good activity and tolerability.(4) Long-term follow-up confirmed these results and u003c50% of all patients had increased BCC lesions at end of study (EOS), where increased numbers of lesions were higher for patients with versus without Gorlin syndrome.(5) Herein, we report patient-assessed HRQoL outcomes from MIKIE.